Physician profile
Brian Stratta
NPI 1730140146
$1,960.97
in general payments reported to CMS, 2019-2025
25 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.40 · 2021: $240 · 2022: $741 · 2023: $446 · 2024: $314 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $351.27 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $318.45 | 2021-2025 | Mavyret |
| Exact Sciences Corporation | $175.19 | 2023-2024 | Cologuard Collection Kit |
| Indivior INC. | $151.58 | 2021-2024 | Sublocade |
| Amgen INC. | $116.66 | 2021-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $107.74 | 2022-2024 | Veozah |
| Pfizer INC. | $77.27 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $71.42 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.79 | 2021-2022 | |
| Abbott Laboratories | $69.71 | 2023 | Freestyle Libre 3, Proclaim |
| Gilead Sciences, INC. | $67.47 | 2022-2023 | Epclusa |
| Novartis Pharmaceuticals Corporation | $52.90 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $44.46 | 2022-2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $44.41 | 2022-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $32.77 | 2024 | Arexvy, Shingrix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $31.96 | 2023 | Vivitrol |
| Lilly USA, LLC | $26.35 | 2022-2025 | Jardiance |
| Sanofi Pasteur INC. | $25.75 | 2021-2022 | |
| Medtronic, INC. | $25.40 | 2022 | |
| Dexcom, INC. | $19.28 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.00 | 2022 | |
| Seqirus USA INC | $18.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.24 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $13.67 | 2022 | |
| Philips North America LLC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.